BioNTech Navigates FDA Vaccine Guidance, Oncology Data, and a Leadership Shake-Up

BioNTech finds itself at a crossroads where three distinct storylines are converging in the same week: a unanimous FDA advisory vote for a new COVID-19 vaccine formulation, a pipeline-heavy presence at the ASCO cancer conference, and the impending departure of its founders to a separate research venture. For a company still wrestling with falling vaccine revenue and a widening net loss, the next few months will test whether its long-term oncology bet can fill the void.

An outside panel of FDA advisers voted 8–0 (with one abstention) on May 28 to recommend updating the COVID-19 shot for the 2026/2027 season to target the XFG variant, a JN.1 sub-lineage that has accounted for more than half of U.S. cases in the four weeks through April 11. The vote came as little surprise — BioNTech had already flagged in its first-quarter report that it was preparing a variant adjustment — but it solidifies regulatory direction for the autumn immunization cycle. Both BioNTech and its partner Pfizer have signaled they are ready to produce the updated formula.

The market’s response was muted. In New York, the stock edged up roughly 0.5% to $93.44, while on the Frankfurt exchange it hovered around €80.70, about 21% below its 52-week peak of €101.90. Investors appear to view the FDA nod as an incremental step rather than a catalyst for a sustained recovery in the COVID business.

Should investors sell immediately? Or is it worth buying BioNTech?

That caution stems from the numbers. BioNTech generated just €118.1 million in revenue during the first quarter of 2026, down sharply from €182.8 million a year earlier, as COVID-19 vaccine sales continued to contract. The net loss swelled to €531.9 million from €415.8 million. Yet the company retains a formidable cushion: €16.76 billion in cash and securities as of March 31, with €9.94 billion in liquid holdings. That firepower is funding a transformation into an oncology powerhouse. Research and development expenses climbed to €557.0 million in the quarter, up from €525.6 million, with spending directed at immuno-oncology programs, antibody-drug conjugates, and costs tied to acquisitions made in 2025.

This week’s ASCO conference is the prime showcase for that effort. BioNTech is highlighting three datasets: Phase 2 results from the PRESERVE-004 study of gotistobart (BNT316) in platinum-resistant ovarian cancer, showing durable tumor activity and survival data; early data on the ADC BNT324/DB-1311 in prostate cancer; and findings on BNT323, a trastuzumab-based conjugate, in recurrent endometrial cancer. Management has set a target of 15 ongoing Phase 3 studies by the end of 2026, up from 13 today.

Complicating the narrative is a leadership transition. Founders U?ur ?ahin and Özlem Türeci plan to move to their own mRNA-focused research company by the end of the year. BioNTech will hold a minority stake and secure rights to certain next-generation technologies. The move does not affect current operations, but it adds an element of uncertainty as the company tries to convince investors that its pipeline can eventually generate revenue that rivals the pandemic-era vaccine gold rush.

BioNTech is sticking to its full-year guidance and continues to run a multibillion-euro share buyback program. Seven more late-stage data readouts are scheduled for the second half of the year. Whether the stock can reclaim its highs will depend on how convincing those results prove — and on the public’s appetite for yet another booster shot this fall.

Ad

BioNTech Stock: New Analysis - 29 May

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECH | boerse | 69439444 |